Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance: Preliminary Results of a Prospective, Single-arm, Phase II Study.

NCT07509424 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT07509424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07509424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance: Preliminary Results of a Prospective, Single-arm, Phase II Study.
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 22, 2026
Completion date
July 10, 2029
Enrollment
29 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer